Search

Your search keyword '"Pfizer Inc. -- Research"' showing total 134 results
Start Over Descriptor "Pfizer Inc. -- Research"
134 results on '"Pfizer Inc. -- Research"'

1. Study Shows Booster Improves Protection for Older People, Pfizer Says

Author

LaFraniere, Sharon

Subjects
BioNTech SE -- Research, Pfizer Inc. -- Research, Viral antibodies -- Analysis, Biotechnology industry -- Research, Antibodies -- Analysis, Pharmaceutical industry -- Research, General interest, News, opinion and commentary
Abstract

Federal officials are hoping that encouraging new findings will spur more Americans to get an updated booster before a feared surge in coronavirus cases this winter. WASHINGTON -- A new [...]

Published
2022

2. Torcetrapib and Atorvastatin-Should marketing drive the research agenda?

Author

Avorn, Jerry

Subjects
Company marketing practices, Pfizer Inc. -- Research, Pfizer Inc. -- Marketing, Torcetrapib (Medication) -- Research, Torcetrapib (Medication) -- Marketing, Pharmaceutical industry -- Research, Pharmaceutical industry -- Marketing
Abstract

Pfizer, which holds the patent on torcetrapib is launching several studies to assess the clinical outcomes of treatment with the drug. Pfizer's trials that study torcetrapib in combination with the company's widely used atorvastatin (Lipitor), may not optimally meet the scientific needs of presribers, the clinical needs of patients and the economical needs of payers but they meet the business needs of the sponsor and thus protect the market share of product.

Published
2005

3. Can Pfizer deliver? It spends $7 billion on R&D. But can it turn out new drugs at a pace that will keep shareholders happy and the public healthy? The answer may lie in how well Pfizer uses technology to improve the drug development process

Author

Rotman, David

Subjects
Pfizer Inc. -- Research, Pharmaceutical industry -- Research
Abstract

DON'T BOTHER MENTIONING 'THE GENOMIC REVOLUTION' these days in the halls of Pfizer's sprawling research and development facility in Groton, CT. Yes, the company's scientists will acknowledge, the latest techniques […]

Published
2004

5. Studies Weigh Antidepressants Against Herbs and Placebos

Author

Bender, Kenneth J.

Subjects
Pfizer Inc. -- Research, Placebos -- Usage -- Research, Depression, Mental -- Drug therapy -- Research, St. John's wort -- Health aspects -- Research -- Usage, Clinical trials -- Evaluation -- Research -- Health aspects -- Usage, Sertraline -- Research -- Health aspects -- Usage -- Evaluation, Pharmaceutical industry -- Health aspects -- Research -- Usage
Abstract

In a study sponsored by the National Institute of Mental Health and published in JAMA, St. John's wort (Hypericum perforatum) was found to be no more effective than placebo for [...]

Published
2003

6. Drug Drought

Author

Herper, Matthew

Subjects
Pharmaceutical industry -- Finance, Pharmaceutical industry -- Management, Pharmaceutical industry -- Research, Pharmaceutical industry -- Product development, Pharmaceutical research -- Finance, Pharmaceutical research -- Evaluation, Company financing, Company business management, Pfizer Inc. -- Research, Pfizer Inc. -- Finance, Pfizer Inc. -- Management, Pfizer Inc. -- Product development
Published
2007

7. SU11248 Shows Early Efficacy and Safety in Imatinib-Resistant GI Stromal Tumors

Subjects
Pfizer Inc. -- Research, Gleevec (Medication) -- Health aspects, Antimitotic agents -- Research, Antineoplastic agents -- Research, Pharmaceutical industry, Drug therapy, Combination
Abstract

A phase III study of SU11248, a cancer medicine being developed by Pfizer to treat imatinib mesylate (Gleevec)-resistant gastrointestinal stromal tumor (GIST), has demonstrated efficacy and safety 7 months ahead [...]

Published
2005

8. New Targets For Drugs

Author

Arnst, Catherine

Subjects
Health care industry, AstraZeneca PLC -- Product development, AstraZeneca PLC -- Research, Bayer Pharmaceuticals Corp. -- Research, Bayer Pharmaceuticals Corp. -- Product development, Onyx Pharmaceuticals Inc. -- Product development, Onyx Pharmaceuticals Inc. -- Research, Pfizer Inc. -- Product development, Pfizer Inc. -- Research, Sorafenib (Medication) -- Product development, Sorafenib (Medication) -- Evaluation, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Research, Health care industry -- Product development, Health care industry -- Research, Drugs -- Product/Service Evaluations, Drugs -- Evaluation, Drugs -- Product development, Cancer -- Drug therapy
Published
2005

9. Amlodipine helps non-hypertensives with CAD

Subjects
Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Amlodipine -- Usage, Antihypertensive drugs -- Usage, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries
Abstract

Amlodipine slows atherosclerosis and reduces the risk of cardiovascular events in individuals with coronary artery disease and normal blood pressure, claim researchers from the USA. The Pfizer-funded two-year study compared [...]

Published
2004

10. CV effects of Celebrex to be studied

Subjects
Pfizer Inc. -- Research, Cardiovascular diseases -- Diagnosis, Pharmaceutical industry -- Research, Medical research -- Planning, Medicine, Experimental -- Planning, Company business planning, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries
Abstract

Pfizer has announced a new study to assess whether celecoxib has an adverse effect on patients with cardiovascular disease. The pharmaceutical company is sponsoring the trial following MSD's recent recall [...]

Published
2004

11. older people; Government critical of drugs research

Subjects
Pfizer Inc. -- Research, Administrative agencies -- Beliefs, opinions and attitudes, Dementia -- Drug use, Mentally ill aged -- Drug use, Pharmaceutical industry -- Research, Psychology and mental health, Sociology and social work
Abstract

Whether an individual receives the drugs they need to help combat dementia still depends on where they live, according to research by drug company Pfizer. But the Department of Health [...]

Published
2004

12. New Studies Reveal Additional Important Health Benefits

Subjects
Pfizer Inc. -- Research, FemHRT (Medication) -- Research -- Health aspects, Estrostep (Contraceptive) -- Research -- Health aspects, Osteoporosis -- Prevention -- Research -- Drug therapy, Hormone therapy -- Physiological aspects -- Health aspects -- Research, Bones -- Density, Acne -- Drug therapy -- Prevention -- Research, Estrogen -- Health aspects -- Research, Oral contraceptives -- Health aspects -- Research
Abstract

2001 NOV 22 - (NewsRx.com & NewsRx.net) -- Pfizer unveiled new data October 23, 2001, on additional health benefits of two of its estrogen compounds at the 57th Annual American [...]

Published
2001

13. PFIZER Inc. and Avant Immunotherapeutics

Subjects
Pfizer Inc. -- Research, AVANT Immunotherapeutics Inc. -- Research, Biological products industry -- Research, Medical equipment -- Research, Medical test kit industry -- Research, Biological products -- Research, Medical equipment and supplies industry -- Research, Physiological apparatus -- Research, Business, Chemicals, plastics and rubber industries
Abstract

PFIZER Inc. and Avant Immunotherapeutics have formed an agreement to develop animal vaccines. Pfizer is paying $2.5 million in up-front licensing fees and is making a $3 million equity investment [...]

Published
2000

14. Pfizer opens new drug discovery center

Subjects
Pfizer Global Research and Development Div -- Research, Pfizer Inc. -- Research, Drugs -- Research, Pharmaceutical industry -- Research, Agricultural industry, Business
Abstract

GROTON, CONN. -- Pfizer Inc. recently opened a new center for the discovery of new drugs for human and animal health at its Groton, Conn., research campus. Pfizer, which recently [...]

Published
2000

15. Geriatric patients in danger

Subjects
Pfizer Inc. -- Research, Medical equipment -- Research -- Health aspects, Aged -- Health aspects -- Research, Medical test kit industry -- Research -- Health aspects, Medical equipment and supplies industry -- Research -- Health aspects, Physiological apparatus -- Research -- Health aspects, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

A continuing study by Pfizer Inc. and RAND has uncovered 22 common conditions and medical care issues that place the elderly at high risk. RAND is a nonprofit institution that [...]

Published
2000

16. Increase in pharmacist interventions leads to healthier patients, Eckerd shows

Author

FREDERICK, JAMES

Subjects
Florida -- Research, Pfizer Inc. -- Research, Eckerd Corp. -- Research, Drugstores -- Research, Health care industry -- Research, Medical care -- Florida -- United States, Health care industry, Business, Pharmaceuticals and cosmetics industries, Retail industry, University of Florida -- Research
Abstract

TAMPA, Fla. -- Patient-care efforts by Eckerd Corp. pharmacists here have led to significant health improvements for patients midway through a year-long study, preliminary results show. The study of pharmacy [...]

Published
1999

17. Novel HIV coreceptor blocker shows promise in trials

Author

Kaye, Donald

Subjects
Pfizer Inc. -- Research, Pharmaceutical industry -- Research, AIDS (Disease) -- Research, AIDS (Disease) -- Care and treatment, AIDS (Disease) -- Drug therapy, HIV (Viruses) -- Research, HIV (Viruses) -- Care and treatment, HIV (Viruses) -- Drug therapy, Health, Health care industry
Published
2004

19. Recruiting patients for Pfizer

Author

Bellucci, Neal M.

Subjects
Pfizer Inc. -- Research, Pfizer Inc. -- Product development, Praxis Communications -- Services, Pharmaceutical research -- Services, Pharmaceutical industry -- Research, Pharmaceutical industry -- Product development, Patients -- Recruiting, Cookery for hypertensives -- Care and treatment, Cookery for hypertensives -- Drug therapy, Hypertension -- Care and treatment, Hypertension -- Drug therapy, Cholesterol -- Care and treatment, Cholesterol -- Drug therapy, African Americans -- testing, Industry hiring, Business, Pharmaceuticals and cosmetics industries
Abstract

Praxis Communications Inc. is helping to recruit patients for a national medical research study that is being conducted by Pfizer Inc. The study, which is under way and focuses on [...]

Published
2004

20. The value of innovation: David Rees assesses the importance of R&D and the rewards it can bring. (Operations Management)

Author

Rees, David

Subjects
Eagle (Helicopter) -- Finance, Eagle (Helicopter) -- Product development, Soap and cleaning agents industry -- Product information, Soap and cleaning agents industry -- Research, Helicopters -- Finance, Helicopters -- Product development, Industrial research -- Evaluation, Pharmaceutical industry -- Research, Industrial research -- United States, Research and development, Company financing, Pfizer Inc. -- Research, Unilever United States Inc. -- Research, Unilever United States Inc. -- Product information
Abstract

The World Trade Center tragedy affected David Metreveli more powerfully than most. The Russian-born Israeli aeronautical engineer had been working on an aerial rescue pod called the Eagle. Like a […]

Published
2002

21. Controlling doctor-patient communication. (DTC Report)

Author

Dickinson, James G.

Subjects
Aventis S.A. -- Research, Schering-Plough Corp. -- Research, Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Business, Health care industry
Abstract

* A new research report says that the use of interactive technologies to support the needs of physicians and patients has changed recently as a result of major initiatives from [...]

Published
2001

22. Vioxx heart-risk evidence mounts; users of Merck's painkiller had more hospitalizations than those on Celebrex

Author

Hensley, Scott

Subjects
Merck & Company Inc. -- Product information, Merck & Company Inc. -- Product defects and recalls, Pfizer Inc. -- Research, Pfizer Inc. -- Product information, Pharmaceutical industry -- Product information, Pharmaceutical industry -- Product defects and recalls, Pharmaceutical industry -- Research, News, opinion and commentary, Vioxx (Medication) -- Product defects and recalls, Vioxx (Medication) -- Research, Celebrex (Medication) -- Research
Published
2004

23. New test may detect Parkinson's early, aid search for drugs

Author

Hensley, Scott

Subjects
Pfizer Inc. -- Research, Speech -- Analysis, Pharmaceutical industry -- Research, Parkinson's disease -- Diagnosis, Business, Business, general
Abstract

Pfizer Corp. has developed a test that uses speech patterns to detect early-stage Parkinson's disease.

Published
2004

24. Efficacy and safety of azithromycin SR compared with minocycline in acne

Subjects
Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Antiacne agents -- Research, Azithromycin -- Research, Minocycline -- Research, Health, Pharmaceuticals and cosmetics industries
Abstract

Sponsored by Pfizer. The primary objective of this study is to evaluate the clinical efficacy of azithromycin micropheres treatment in outpatients with moderate to severe inflammatory acne compared with first-line [...]

Published
2007

25. New Pfizer drug shows promise for transplants

Author

Hensley, Scott

Subjects
Pfizer Inc. -- Product development, Pfizer Inc. -- Research, Transplantation of organs, tissues, etc. -- Drug therapy, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Research, Business, Business, general
Published
2003

26. Researchers Find Zoloft, a Popular Antidepressant, to Be Effective in Treating Children

Author

Goode, Erica

Subjects
Pfizer Inc. -- Research, Zoloft (Medication) -- Usage -- Research -- Health aspects, Antidepressants -- Usage -- Health aspects -- Research, Depression in children -- Drug therapy -- Research, Pharmaceutical research -- Usage -- Health aspects -- Research
Abstract

Zoloft, a commonly prescribed antidepressant, is effective for treating moderate to severe depression in children and adolescents, researchers are reporting today. The research, the largest published study of children to […]

Published
2003

27. Pfizer's hopes: antismoking pill, Lipitor for diabetes; company cites a study showing its cholesterol-lowering drug can mitigate diabetics' problems

Author

Winslow, Ron

Subjects
Pfizer Inc. -- Product information, Pfizer Inc. -- Research, Pharmaceutical industry -- Product information, Pharmaceutical industry -- Research, Statins -- Health aspects, Statins -- Research, Diabetes -- Drug therapy, Business, Business, general, Lipitor (Medication) -- Research, Lipitor (Medication) -- Health aspects
Published
2003

28. Pfizer will delay its filings to FDA to boost drug data

Author

Hensley, Scott

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Business, Business, general, Pregabalin (Medication) -- Laws, regulations and rules
Published
2001

30. Pfizer halts its trials on a painkiller after cautions

Subjects
Pfizer Inc. -- Research, Pregabalin (Medication) -- Testing, Drugs -- Research, Pharmaceutical industry -- Research
Abstract

The Pfizer Corporation has halted some clinical trials of a painkilling medication after federal regulators voiced concern over a study suggesting the medication increased the incidence of tumors in mice. […]

Published
2001

32. Talking back is good medicine

Author

Brock, Fred

Subjects
Information services industry, Pfizer Inc. -- Research, Aged -- Care and treatment -- Ethical aspects -- Beliefs, opinions and attitudes, Medical professions -- Beliefs, opinions and attitudes -- Methods -- Research, Physician and patient -- Ethical aspects -- Research -- Methods, Information services industry -- Ethical aspects -- Quality management, Drugs -- Research -- Ethical aspects -- Quality management, Physicians -- Beliefs, opinions and attitudes -- Ethical aspects, Patient advocacy -- Methods -- Research, Information services -- Ethical aspects -- Quality management, Medical care -- Quality management, Pharmaceutical industry -- Ethical aspects
Abstract

TWO years ago, Esther Weiss traveled from her home in Encino, Calif., to her hometown of Kansas City, Mo., to help celebrate her sister's 90th birthday. Upon arriving, she found […]

Published
2001

35. Boehringer talks with Pfizer over link-up

Author

Firn, David and Michaels, Adrian

Subjects
Pfizer Inc. -- Research, Surgical equipment and supplies industry -- Research, Banking, finance and accounting industries, Business, Business, international
Abstract

Boehringer Ingelheim is in advanced talks with Pfizer over sharing sales revenues from a promising treatment for lung disease. Four major pharmaceuticals groups are in the running to co-promote and [...]

Published
2000

37. Pfizer halts tests of drug for 2 types of cancer

Subjects
Pfizer Inc. -- Research, Prinomastat (Medication) -- Evaluation -- Product/service Evaluations, Drugs -- Research -- Evaluation -- Product/service Evaluations, Pharmaceutical industry -- Research
Abstract

Pfizer Inc. said yesterday that it had halted two advanced tests of an experimental drug after studies did not show the expected benefits in patients with prostate and lung cancer. […]

Published
2000

38. Pfizer plans to cut R&D budget 6% on redundancy

Author

Hensley, Scott

Subjects
Pfizer Inc. -- Research, Warner-Lambert Co. -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Finance, Pharmaceutical research -- Planning, Business, Business, general
Published
2000

39. UK: PFIZER TESTS NEW VERSION OF VIAGRA

Subjects
United Kingdom -- Research, Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Business, Business, international, Retail industry, Viagra (Medication) -- Research
Abstract

Pfizer is understood to be planning formal tests of a new version of Viagra, the anti-impotence treatment, which users would inhale and may offer an advantage over the conventional pill version in that takes less time to have an effect. Scientists at the pharmaceuticals group's Sandwich-based research laboratories in the UK submitted a patent around a year and a half ago describing a new type of sildenafil, the heart drug used to develop Viagra, The new version can be absorbed in water and subsequently may be used as a nasal spray.

Published
2000

40. Pfizer discovers way to measure arousal in women with MRI

Subjects
Pfizer Inc. -- Research, EPIX Medical Inc. -- Research, Pharmaceutical industry -- Research, Sexual excitement -- Research, Sexual disorders -- Research, Magnetic resonance imaging -- Usage, Women -- Research, Business, Business, general
Published
1999

41. Scientists see hope in new class of cancer drugs

Author

Langreth, Robert

Subjects
ImClone Systems Inc. -- Research, AstraZeneca PLC -- Research, Pfizer Inc. -- Research, Cancer -- Drug therapy, Pharmaceutical industry -- Research, Antineoplastic agents -- Research, Biotechnology industry -- Research, Business, Business, general
Published
1999

42. Recipe for R&D success - 'Get Lucky.' (pharmaceutical industry)

Author

Dower, Moira

Subjects
Pfizer Inc. -- Research, SmithKline Beecham Corp. -- Research -- 00307917, Zeneca Ltd. -- Research, Bristol-Myers Squibb Co. -- Research -- 00301155, Pharmaceutical industry -- Research, Business, Pharmaceuticals and cosmetics industries
Published
1996

43. From genetics, a promising cholesterol drug

Author

Waldholz, Michael

Subjects
Bristol-Myers Squibb Co. -- Research, Glaxo Holdings PLC -- Research, Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Hypercholesterolemia -- Drug therapy, Heart diseases -- Drug therapy, Blood cholesterol -- Genetic aspects, Business, Business, general
Published
1998

44. Five countries targeted in new trachoma initiative

Author

Sharp, David

Subjects
Edna McConnell Clark Foundation -- Research, Zithromax (Medication) -- Health aspects, Pharmaceutical industry -- Research, Trachoma -- Prevention, Azithromycin -- Health aspects, Blindness -- Prevention, Pfizer Inc. -- Research
Published
1998

45. Exubera poses cancer risk

Subjects
Pfizer Inc. -- Research, Inhaled medication -- Research, Cancer -- Risk factors -- Complications and side effects, Pharmaceutical industry -- Research, Business, Pharmaceuticals and cosmetics industries, Retail industry, Exubera (Medication) -- Complications and side effects -- Research
Abstract

Pfizer Inc. confirms that clinical trials involving Exubera, an inhaled form of insulin, found increased cases of lung cancer. Consequently, Pfizer and partner Nektar Therapeutics Inc. have suspended talks with [...]

Published
2008

46. Pfizer to spend 11% more in '94 on research

Author

Anders, George

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Business, Business, general, Glucotrol (Medication) -- Licensing agreements
Published
1994

49. A pipeline push

Author

Mullin, Rick

Subjects
Pfizer Inc. -- Company sales and earnings, Pfizer Inc. -- Product development, Pfizer Inc. -- Research, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Research, Company earnings/profit, Chemicals, plastics and rubber industries, Engineering and manufacturing industries
Abstract

The world's largest drug company, Pfizer, has reduced its US sales force by 20 % as the introduction of the new drugs in the market is reduced since the 1990s. The company is pursing research programmes, acquisitions, partnership, and licensing and is involved in 242 development program in 11 different therapeutic regions which will generate new drugs for unmet medical needs.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results